EBC is a platform for patients, health professionals, scientists & industry that promotes brain research in Europe and improved quality of life for patients.
7 07-2021

GOLUP Consortium holds a digital event on “Patient Safety and Informed Consent: The Importance of Good Off-label Use Practices” 

2021-07-15T15:07:34+00:0007-07-2021|News|

Event Report: “Patient Safety and Informed Consent: The Importance of Good Off-label Use Practices”  On 17 June 2021, the GOLUP (Good Off-label Use Practices) Consortium held a virtual event, led by the European Brain Council, to disseminate the Declaration on Good Off-Label Use Practice.  The event was hosted by MEP Cyrus Engerer (S&D, Malta), member of the Committee on the Environment, Public Health and [...]

5 07-2021

EBC supports the need to prioritise the rapidly growing challenge of Alzheimer’s disease

2021-07-07T11:46:51+00:0005-07-2021|News|

Alzheimer’s disease (AD) is a neurodegenerative disease that progresses in stages, beginning with a long silent phase before symptoms occur, and the underlying cause in 70% of people with dementia. Dementia, which is not a specific disease but an overall term that describes a group of symptoms, is characterized by a decline in memory, thinking, [...]

28 06-2021

VOT2 Case Studies on Rare Diseases & Mental Disorders present findings at Synthesis Meeting on 8 June 2021

2021-06-28T10:01:34+00:0028-06-2021|News|

On 8 June 2021, EBC hosted a virtual Synthesis Meeting for the Value of Treatment 2 case study working groups to present their preliminary findings. The Value of Treatment for Brain Disorders (VOT) is a health economics and outcomes research project coordinated by the European Brain Council (EBC). EBC conceptualized in 2015 the Value [...]

28 06-2021

EBC raises awareness on International Phenylketonuria Day

2021-06-28T07:41:17+00:0028-06-2021|News|

EBC is happy to recognise and support International Phenylketonuria (PKU) Day, which takes place annually on 28 June — the birthday of two stalwarts of PKU, Robert Guthrie (1916-1995) and Horst Bickel (1918-2000). The ongoing 2019-2021 Value of Treatment (VOT) project for Brain Disorders and its recent synthesis meeting on 8 June 2021 aimed to [...]

18 06-2021

Save the Date and Call for Applications Launched for Brain Innovation Days

2021-06-21T14:18:07+00:0018-06-2021|News|

We are excited to announce that after one year of digital sessions, the Brain Innovation Days will take place in person on 12-13 October 2021 in Brussels, Belgium. Under the overarching theme, United for Brain Innovation, the Brain Innovation Days will bring together key opinion leaders and stakeholders from the ever-growing brain innovation ecosystem to create [...]

8 06-2021

The Value of Treatment for Brain Disorders: Case Studies on Rare Diseases & Mental Disorders present findings at Synthesis Meeting

2021-06-08T08:21:59+00:0008-06-2021|News|

The Value of Treatment for Brain Disorders (VOT) is a health economics and outcomes research project coordinated by the European Brain Council (EBC). EBC conceptualized the Value of Treatment research framework to address the increasing burden of brain disorders – both neurological and mental alike. Budgetary restrictions across the EU are threatening the sustainability [...]

27 05-2021

EBC launches “RETHINKING MS in times of COVID-19” on the occasion of World Multiple Sclerosis Day

2021-06-28T07:51:36+00:0027-05-2021|News|

On the occasion of the approaching World Multiple Sclerosis Day (30 May 2021), the European Brain Council is excited to announce the release of its new policy paper, "RETHINKING MS in times of COVID-19". This new paper is part of the main report "RETHINKING MS in Europe", a research-driven project offering tangible policy changes [...]

25 05-2021

Registration open for “Patient safety and informed consent: The importance of good off-label use practices” event on 17 June 2021

2021-05-25T11:13:44+00:0025-05-2021|News|

The European Brain Council is pleased to invite you to register for the digital event "Patient safety and informed consent: The importance of good off-label use practices" to be held virtually on 17 June 2021 at 14:30 - 16:00CET. The event is co-organised with EUCOPE. In 2016, the Declaration for Good Off-Label Use Practice was launched, supported [...]

19 05-2021

IMI PARADIGM develops toolkit to make patient engagement in medicines development easier for all

2021-05-20T11:55:20+00:0019-05-2021|News|

There is consensus among stakeholders that patient engagement at different points of the medicines lifecycle is critical to fostering patient access to innovative therapeutic solutions, and delivering better health outcomes for patients.  IMI PARADIGM, a public private consortium consisting of patients, academia, industry, HTA bodies and regulators, developed a toolkit to make patient engagement [...]

Go to Top